Cullinan Therapeutics, Inc.
$14.52
▲
3.52%
2026-04-21 06:00:01
cullinantherapeutics.com
NMS: CGEM
Explore Cullinan Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$911.52 M
Current Price
$14.52
52W High / Low
$16.74 / $5.68
Stock P/E
—
Book Value
$6.79
Dividend Yield
—
ROCE
-58.85%
ROE
-44.02%
Face Value
—
EPS
$-3.36
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
109
Beta
-0.11
Debt / Equity
0.66
Current Ratio
10.25
Quick Ratio
10.25
Forward P/E
-5.06
Price / Sales
—
Enterprise Value
$504.84 M
EV / EBITDA
-2.09
EV / Revenue
—
Rating
Strong Buy
Target Price
$31.35
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Erasca, Inc. | $21.71 | — | $5.91 B | — | -35.74% | -33.27% | $19.78 / $1.06 | $1.14 |
| 2. | Nkarta, Inc. | $3.49 | — | $247.38 M | — | -31.94% | -28.9% | $3.48 / $1.63 | $4.39 |
| 3. | Hyperion DeFi, Inc. | $4.28 | — | $48.76 M | — | -38.69% | -3.24% | $17.18 / $1.02 | $4.73 |
| 4. | Rigel Pharmaceuticals, Inc. | $32.49 | 1.65 | $604.16 M | — | 30.28% | 1.86% | $52.24 / $16.11 | $21.38 |
| 5. | Olema Pharmaceuticals, Inc. | $16.58 | — | $1.47 B | — | -37.1% | -36.61% | $36.26 / $3.89 | $5.88 |
| 6. | Enanta Pharmaceuticals, Inc. | $13.78 | — | $409.17 M | — | -36.76% | -60.01% | $17.15 / $4.83 | $4.36 |
| 7. | Cogent Biosciences, Inc. | $37 | — | $6.05 B | — | -38.16% | -73.7% | $43.73 / $4.12 | $3.4 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -55.26 M | -55.59 M | -75.8 M | -55 M | -55.05 M | — |
| Net Profit | -50.71 M | -50.61 M | -70.06 M | -48.5 M | -47.65 M | — |
| EPS in Rs | -0.84 | -0.84 | -1.16 | -0.8 | -0.79 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -241.65 M | -196.92 M | -190.65 M | -132.14 M |
| Net Profit | -219.88 M | -167.38 M | -153.16 M | 111.21 M |
| EPS in Rs | -3.63 | -2.77 | -2.53 | 1.84 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 448.37 M | 621.82 M | 484.18 M | 561.12 M |
| Total Liabilities | 39.64 M | 31.5 M | 30.29 M | 26.09 M |
| Equity | 408.73 M | 590.33 M | 453.7 M | 535.03 M |
| Current Assets | 386.76 M | 414.67 M | 480.19 M | 474.47 M |
| Current Liabilities | 37.74 M | 30.65 M | 28.14 M | 22.5 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -175.75 M | -145.3 M | -134.28 M | -126.66 M |
| Investing CF | 179.99 M | -136.31 M | 35.81 M | 248.97 M |
| Financing CF | 1.09 M | 266.19 M | 40.75 M | -25.93 M |
| Free CF | -175.8 M | -145.3 M | -134.48 M | -127.8 M |
| Capex | -0.05 M | — | -0.21 M | -1.13 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -9.28% | -237.72% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.